Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06091098 · ClinicalTrials.gov registry record · NA
Reversible Effect of Falling Ventilatory Drive in Drive-dependent OSA
A NA study of OSA, sponsored by Brigham and Women's Hospital.
- Recruiting
- Registry status
- NA
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT06091098: Recruiting NA study of OSA, sponsored by Brigham and Women's Hospital.
NCT06091098 is a NA study of OSA that is actively recruiting participants, run by Brigham and Women's Hospital. The registered enrollment target is 36 participants, below the 163-participant average among 14 other OSA trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06091098, a NA study of OSA, is actively recruiting participants, sponsored by Brigham and Women's Hospital.
- RECRUITING
- Registry status
- NA
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
Obstructive sleep apnea (OSA) is a highly prevalent disorder that has major consequences for cardiovascular health, neurocognitive function, risk of traffic accidents, daytime sleepiness, and quality of life. For years, a "classic" model of OSA has been used to describe the disorder, which fails to capture it's complexity. Recently, a model for OSA called drive-dependent OSA was discovered be more prevalent in the OSA population. The drive-dependent subgroup benefits exclusively from increased ventilation, increased dilator muscle activity, and reduced event risk when drive spontaneously rises. This study seeks to provide direct evidence that reducing the loss of drive prevents the loss of ventilation, pharyngeal muscle activity, and thus the onset of OSA respiratory events, specifically in "drive-dependent" but not "classic" OSA. This will be achieved using CO2 delivered at precise times during breaths in sleep to prevent loss of overall ventilatory drive.
Primary Outcome
Active versus sham ventilatory drive intervention, difference between drive-dependent OSA and classic OSA subgroups
Conditions Studied
Interventions
- OTHER Dynamic CO2
- OTHER Sham CO2
Study Locations (1)
Massachusetts
- Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2024-03-27 |
| Est. Completion | 2027-12-31 |
| Phase | NA |
What NCT06091098 shows while recruiting
NCT06091098 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 163-participant average among 14 other OSA trials with a reported enrollment target (78% lower).
The record links to 1 condition, with OSA appearing as the primary indexed condition, and to 2 interventions - of which Dynamic CO2 is the first listed.
NCT06091098 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06091098 about?
NCT06091098 is a clinical study titled "Reversible Effect of Falling Ventilatory Drive in Drive-dependent OSA". Obstructive sleep apnea (OSA) is a highly prevalent disorder that has major consequences for cardiovascular health, neurocognitive function, risk of traffic accidents, daytime sleepiness, and quality of life. For years, a "classic" model of OSA has been used to describe the disorder, which fails to ...
What is the current status of trial NCT06091098?
This trial is currently recruiting. It is a NA study. The enrollment target is 36 participants. The study started on 2024-03-27. Estimated completion is 2027-12-31.
What conditions does trial NCT06091098 study?
This clinical trial studies the following conditions: OSA.
What interventions are being tested in trial NCT06091098?
The interventions under investigation include: Dynamic CO2 (OTHER), Sham CO2 (OTHER).
Who is sponsoring clinical trial NCT06091098?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06091098 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for OSA
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06091098's enrollment target sits among peer trials
36 8th of 14 higher than 5 of 14 other OSA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other OSA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Mandibular Advancement Device and Changes in Nocturia
RECRUITING · NA
-
The Effect of Interval Exercise on Functional Outcomes in Veterans With COPD and OSA
RECRUITING · NA
-
Treating Obstructive Sleep Apnea Using Targeted Hypoglossal Neurostimulation
ACTIVE NOT RECRUITING · NA
-
Sham CPAP vs. Straight CPAP for Chronic Cough
COMPLETED · NA
-
Early Feasibility Study of Transcutaneous Upper Airway Stimulation in Obstructive Sleep Apnea
COMPLETED · NA
-
Novel by Upper Airway Respiratory Muscle Training to Treat OSA in Chronic SCI
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI